STOCK TITAN

Pacira BioSciences: $36.50 offer clears minimum

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SC TO-T/A

Rhea-AI Filing Summary

Pacira BioSciences, Inc. (PCRX) is the target of a cash tender offer by Viatris subsidiary Peach Purchaser Sub for all outstanding common shares at $36.50 per share, net of applicable withholding taxes and without interest. The offer expired as scheduled on November 16, 2026; 32,929,780 shares, approximately 66.46% of shares outstanding immediately before expiration, were validly tendered and not withdrawn. The buyer accepted all such shares for payment on November 17, 2026, with payment to be made promptly under the offer terms.

The tendered shares, together with shares then owned by the buyer and its affiliates, satisfied the Minimum Condition, excluding guaranteed-delivery shares not yet received for that condition. The remaining merger conditions were satisfied or waived, and Peach Purchaser Sub will merge into Pacira on November 17, 2026, without a Pacira stockholder vote. At the merger’s effective time, eligible outstanding shares convert into the right to receive the offer price; specified company- and buyer-held shares are canceled, while properly perfected appraisal-right shares are excluded. After the merger, Pacira shares will be delisted and cease trading on the Nasdaq Global Select Market.

Tender offer price $36.50 per share Cash consideration, net of applicable withholding taxes and without interest
Shares validly tendered 32,929,780 shares Validly tendered and not withdrawn immediately prior to expiration
Tendered share percentage Approximately 66.46% Percentage of Pacira shares outstanding immediately prior to expiration
Minimum Condition regulatory
"satisfied the Minimum Condition"
guaranteed delivery procedures technical
"tendered pursuant to guaranteed delivery procedures"
Guaranteed delivery procedures are a settlement arrangement that lets a buyer or seller complete a trade even when the actual shares or cash cannot be delivered immediately, by promising to provide them within a short, specified window. For investors this works like reserving and paying for an item that will be shipped later: it reduces the risk of a failed trade and allows participation in offerings or market trades despite paperwork or transfer delays, but it also means you should watch the final settlement date and counterparty obligations.
appraisal rights regulatory
"demand appraisal rights under"
A legal right that lets shareholders who dislike the price or terms of a buyout, merger or other major corporate change ask for an independent determination of the fair value of their shares instead of accepting the deal price. Think of it like asking a neutral referee to set the payout if you believe the offered price is too low. For investors, appraisal rights can provide a way to recover a higher cash value but can be slow, costly and create uncertainty around deal outcomes.
Effective Time regulatory
"at the Effective Time"
The exact clock time when a regulatory filing, approval, or corporate action formally becomes legally active; from that moment the change is binding and can be acted on. Investors care because the effective time marks when ownership, rights, trading rules, or new securities take effect — like a light switch turning on a contract or transaction — which determines when risks, benefits and market reactions begin.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PCRX shares were tendered in the Viatris offer?

A total of 32,929,780 shares were validly tendered and not withdrawn, representing approximately 66.46% of Pacira shares outstanding immediately before the offer expired. Peach Purchaser Sub accepted all those shares for payment on November 17, 2026.

What was the cash offer price for Pacira shares?

The offer price was $36.50 per share in cash, net of applicable withholding taxes and without interest. At the merger’s effective time, eligible outstanding shares convert into the right to receive that amount, subject to the merger agreement’s terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE TO
(Amendment No. 2)
Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934
PACIRA BIOSCIENCES, INC.
(Name of Subject Company)
PEACH PURCHASER SUB INC.
(Offeror)
A Wholly Owned Subsidiary of
VIATRIS INC.
(Parent of Offeror)
(Names of Filing Persons (identifying status as offeror, issuer or other person))
COMMON STOCK, PAR VALUE $0.001 PER SHARE
(Title of Class of Securities)
695127100
(CUSIP Number of Class of Securities)
Matthew J. Maletta
Chief Legal Officer
Viatris Inc.
1000 Mylan Boulevard
Canonsburg, Pennsylvania 15317
(724) 514-1800
(Name, address and telephone number of person authorized to receive notices and communications on behalf of filing persons)
with copies to:
Mark I. Greene
Aaron M. Gruber
Andrew M. Wark
Cravath, Swaine & Moore LLP
Two Manhattan West
375 Ninth Avenue
New York, NY 10001
(212) 474-1000

☐
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
Check the appropriate boxes below to designate any transactions to which the statement relates:
 
☒
third-party tender offer subject to Rule 14d-1.
 
☐
issuer tender offer subject to Rule 13e-4.
 
☐
going-private transaction subject to Rule 13e-3.
 
☐
amendment to Schedule 13D under Rule 13d-2.
Check the following box if the filing is a final amendment reporting the results of the tender offer: ☒
If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:
 
☐
Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
 
☐
Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)



This Amendment No. 2 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO (as amended and together with any subsequent amendments and supplements thereto, the “Schedule TO”), filed with the U.S. Securities and Exchange Commission on October 30, 2026, by Peach Purchaser Sub Inc., a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Viatris Inc., a Delaware corporation (“Viatris”), and Viatris. The Schedule TO relates to the tender offer (the “Offer”) by Purchaser for all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Pacira BioSciences, Inc., a Delaware corporation (“Pacira”), for $36.50 per Share, to the seller thereof in cash, net of applicable withholding taxes and without interest (the “Offer Price”), upon the terms and subject to the conditions set forth in the Agreement and Plan of Merger dated October 8, 2026 (the “Merger Agreement”), among Pacira, Viatris and Purchaser.

Except to the extent specifically provided in this Amendment, the information set forth in the Schedule TO remains unchanged. This Amendment is being filed to reflect certain updates as reflected below. Capitalized terms used but not defined herein have the respective meanings ascribed to them in the Schedule TO.

Items 1 through 9 and 11
The Offer to Purchase dated October 30, 2026 (together with any amendments and supplements thereto, the “Offer to Purchase”), a copy of which was filed as Exhibit (a)(1)(A) to the Schedule TO, and Items 1 through 9 and Item 11 of the Schedule TO, to the extent such Items incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented as follows:

“The Offer and related withdrawal rights expired as scheduled at one minute after 11:59 p.m., Eastern Time, on November 16, 2026 (such date and time, the “Expiration Time”), and the Offer was not extended. Equiniti Trust Company, LLC, the depositary for the Offer, advised Purchaser that, immediately prior to the Expiration Time, a total of 32,929,780 Shares were validly tendered (and not validly withdrawn) pursuant to the Offer, representing approximately 66.46% of the Shares outstanding immediately prior to the Expiration Time. As of the Expiration Time, the number of Shares validly tendered (and not validly withdrawn) pursuant to the Offer (excluding Shares tendered pursuant to guaranteed delivery procedures that have not yet been “received,” as such term is defined in Section 251(h)(6)(f) of the General Corporation Law of the State of Delaware (the “DGCL”), by the “depository,” as such term is defined in Section 251(h)(6)(c) of the DGCL), together with any Shares then owned by Purchaser and its affiliates, satisfied the Minimum Condition (as defined in the Merger Agreement). All other conditions to the consummation of the Offer having been satisfied or waived, on November 17, 2026, Purchaser irrevocably accepted for payment all Shares that were validly tendered (and not validly withdrawn) pursuant to the Offer, and payment for such Shares will be made promptly in accordance with the terms of the Offer and the Merger Agreement.
Following the Expiration Time and acceptance for payment of the Shares, the remaining conditions to the Merger (as defined below) set forth in the Merger Agreement were satisfied or waived, and Purchaser will consummate the Merger on November 17, 2026, without a vote of the stockholders of Pacira in accordance with Section 251(h) of the DGCL. At the Effective Time (as defined below), Purchaser will be merged with and into Pacira, the separate existence of Purchaser will cease and Pacira will continue as the surviving corporation in the Merger and a wholly owned subsidiary of Viatris (the “Merger,” and the date and time at which the Merger becomes effective is referred to as the “Effective Time”). Pursuant to the Merger Agreement, at the Effective Time, each Share issued and outstanding immediately prior to the Effective Time (other than Shares that are held (i) by Pacira or any of its subsidiaries (including in Pacira’s treasury), (ii) by Viatris, Purchaser or any other wholly owned direct or indirect subsidiary of Viatris, which Shares will be canceled and will cease to exist, and no consideration will be delivered in exchange therefor, or (iii) by Pacira stockholders who are entitled to demand appraisal rights under, and have properly exercised and perfected their respective demands for appraisal of such Shares in the time and manner provided in, Section 262 of the DGCL and, as of the Effective Time, have neither effectively withdrawn nor lost their rights to such appraisal and payment under the DGCL) will be converted into the right to receive the Offer Price, upon the terms and conditions set forth in the Merger Agreement.

Following the consummation of the Merger, the Shares will be delisted and will cease to trade on the Nasdaq Global Select Market. Pursuant to the terms of the Merger Agreement, Viatris and Pacira will take steps to cause the Shares to be deregistered under the Securities Exchange Act of 1934, as amended, as promptly as practicable after the Effective Time.

On November 17, 2026, Viatris issued a press release announcing the expiration and results of the Offer. The press release is attached as Exhibit (a)(5)(E) hereto, and is incorporated herein by reference.”


Item 12. Exhibits.

Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibit:

 
“(a)(5)(E)
 
 
Press Release issued by Viatris on November 17, 2026.*”
 
   
   
*
Filed herewith.


SIGNATURES
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
VIATRIS INC.
 
By
       
   
/s/ Matthew J. Maletta
   
Name:
Matthew J. Maletta
   
Title:
Chief Legal Officer
   
Date:
November 17, 2026

 
PEACH PURCHASER SUB INC.
 
By
       
   
/s/ Michael Rainerman
   
Name:
Michael Rainerman
   
Title:
President
   
Date:
November 17, 2026

[Signature Page to Amendment No. 2 to Schedule TO-T]


Keep reading